Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 16/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 7/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2189383 | 1.00 | CACNA1B (0.55) | CACNA1BNR1I2CYP3A4DRD2ADRA1D | |
| SCHEMBL2188313 | 0.95 | CACNA1B (0.51) | CACNA1BNR1I2CYP3A4DRD2ADRA1D | |
| SCHEMBL2188631 | 0.95 | CACNA1B (0.51) | CACNA1BNR1I2CYP3A4DRD2ADRA1D | |
| SCHEMBL2190414 | 0.90 | CACNA1B (0.50) | CACNA1BNR1I2CYP3A4OPRM1OPRL1 | |
| SCHEMBL2189827 | 0.90 | CACNA1B (0.50) | CACNA1BNR1I2CYP3A4OPRM1OPRL1 | |
| SCHEMBL12415663 | 0.90 | CACNA1B (0.50) | CACNA1BNR1I2CYP3A4OPRM1OPRL1 | |
| SCHEMBL2188437 | 0.89 | CACNA1B (0.49) | CACNA1BNR1I2CYP3A4DRD2ADRA1D | |
| SCHEMBL2190435 | 0.89 | CACNA1B (0.49) | CACNA1BNR1I2CYP3A4DRD2ADRA1D | |
| SCHEMBL2191904 | 0.87 | CACNA1B (0.45) | CACNA1BNR1I2CYP3A4DRD2ADRA1D | |
| SCHEMBL2189711 | 0.87 | CACNA1B (0.45) | CACNA1BNR1I2CYP3A4DRD2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CHAKRAVARTY PRASUN K | 2011-07-14 | — | — | US | claimed |
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CHAKRAVARTY PRASUN K | 2011-07-14 | — | — | US | disclosed |
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CHAKRAVARTY PRASUN K | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, TRPA1, CACNA1D | CACNA1B 23/4885NR1I2 765/4885CYP3A4 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.